CD8A and glioblastoma: To delineate the TME more accurately in clinical patients, 64Cu-DOTA-IAB22M2C, a CD8-targeted minibody, has been effectively used in a xenograft model of orthotopic glioblastoma, demonstrating its ability to monitor both peripheral and intratumoral CD8+ T cells (79).